INSIGHTS ON DRUG DEVELOPMENT

DRUG DEVELOPMENT SOLUTIONS

  • Our HPAPI development and manufacturing spans preclinical through commercial supply across 13 global sites, with SafeBridge-certified containment and 30 years of cytotoxic compound expertise.

  • Early identification of potential absorption risks is critical for rapid and efficient drug development. Lonza's PBPK modeling services are designed to de-risk your drug development program.

  • Enhance tablet effectiveness across various dosages with an excipient that offers excellent compressibility and stability for APIs, which eliminates the need for intense processing and provides rapid disintegration.

  • SimpleStep ELISA® kits are sandwich ELISA assays that we have developed to be as simple and effective as possible. Unlike traditional sandwich ELISAs, which take more than three hours to run, SimpleStep ELISA kits generate data in just 90 minutes without compromising performance, using only one wash step and recombinant antibodies for exceptional specificity.

  • A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.